Eli Lilly has released historic long-term data from the Omvoh mirikizumab-mrkz clinical trials, proving that the IL-23p19 antagonist maintains high rates of “disease clearance” through four years of treatment.
Eli Lilly has received FDA approval for a new single-injection maintenance dose of Omvoh (mirikizumab-mrkz) for adults with moderately to severely active ulcerative colitis. This approval simplifies the treatment regimen from two monthly injections down to just one, offering the same proven efficacy in a more convenient format. The new 200 mg/2 mL prefilled pens and syringes are expected to be available in the U.S. in early 2026.
